<DOC>
	<DOCNO>NCT01015209</DOCNO>
	<brief_summary>The `` dry eye syndrome '' DES highly prevalent ocular disease , particular elderly population . One mainstay therapy patient suffer DES use topically administer lubricant . However , despite many effort , `` ideal '' formulation yet find . Recently , Croma Pharma introduce chitosan-N-acetylcysteine eye drop , design treatment symptom related DES . Chemically , chitosan polycationic biopolymer favourable biological property high biocompatibility low toxicity . Additionally , new formulation comprise N-acetylcysteine , use ophthalmology mucolytic property several year . Based theoretical consideration , one hypothesize new chitosan derivative may show increased adhesion mucin ocular surface may therefore particularly beneficial reduce symptom associate DES .</brief_summary>
	<brief_title>Safety Tolerability Chitosan-N-acetylcysteine Eye Drops Healthy Young Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Dry Eye Syndromes</mesh_term>
	<mesh_term>Keratoconjunctivitis Sicca</mesh_term>
	<mesh_term>Acetylcysteine</mesh_term>
	<mesh_term>N-monoacetylcystine</mesh_term>
	<mesh_term>Tetrahydrozoline</mesh_term>
	<mesh_term>Chitosan</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Men woman age 18 45 year Normal laboratory value unless investigator considers abnormality clinically irrelevant Normal finding medical history physical examination unless investigator considers abnormality clinically irrelevant Normal ophthalmic finding , ametropia &lt; 6 dpt . Participation clinical trial 3 week precede study Abuse alcoholic beverage Symptoms clinically relevant illness 3 week first study day Ametropia 6 dpt . Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Dry eye syndrome</keyword>
</DOC>